Donald Kalff earned a PhD from the Wharton School of the University of Pennsylvania, Philadelphia (US).
Following a period in academia as assistant professor at the Graduate School of Management in Delft, Dr Kalff joined Royal Dutch/Shell in 1980. At Shell he carried out assignments in marketing, oil and products trading, and in corporate and strategic planning, both in the Netherlands and the UK.
Ten years later Dr Kalff joined KLM Royal Dutch Airlines to become a member of the Executive Board, responsible for air political affairs, institutional relations, business planning, fleet planning and acquisition, and strategic alliances. From 1997 until 2000 he was KLM’s chief negotiator for mergers and long-term agreements.
Today, Dr Kalff is co-founder and CEO of Immpact, a biotech start-up company working in the field of immunology, and advisor to the biotech investment fund BTF and to strategy consultants Roland Berger.
Dr Kalff has a long-standing interest in cancer research and has sponsored a number of projects in the field. He is divorced and lives in the Netherlands and France.
Website : http://www.donaldkalff.eu/